American Association for Cancer Research
10780432ccr190475-sup-216885_3_supp_5641295_pv96st.png (127.97 kB)

Figure S2 from Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Download (127.97 kB)
posted on 2023-03-31, 21:11 authored by Jiayi Yu, Junya Yan, Qian Guo, Zhihong Chi, Bixia Tang, Bin Zheng, Jinyu Yu, Ting Yin, Zhiyuan Cheng, Xiaowen Wu, Huan Yu, Jie Dai, Xinan Sheng, Lu Si, Chuanliang Cui, Xue Bai, Lili Mao, Bin Lian, Xuan Wang, Xieqia Yan, Siming Li, Li Zhou, Keith T. Flaherty, Jun Guo, Yan Kong

Supplementary Figure S2. The PD-1 staining of C57BL/6-hPD-1 mice.


Natural Science Foundation of China

Health Science Center



PD-1 checkpoint blockade immunotherapy induces long and durable response in patients with advanced melanoma. However, only a subset of patients with melanoma benefit from this approach. The mechanism triggering the innate resistance of anti–PD-1 therapy remains unclear.Experimental Design: Whole-exome sequencing (WES) and RNA sequencing (RNA-Seq) analyses were performed in a training cohort (n = 31) using baseline tumor biopsies of patients with advanced melanoma treated with the anti–PD-1 antibody. Copy-number variations (CNVs) for the genes CDK4, CCND1, and CDKN2A were assayed using a TaqMan copy-number assay in a validation cohort (n = 85). The effect of CDK4/6 inhibitors combined with anti–PD-1 antibody monotherapy was evaluated in PD-1–humanized mouse (C57BL/6-hPD-1) and humanized immune system (HIS) patient-derived xenograft (PDX) models. WES revealed several significant gene copy-number gains in the patients of no clinical benefit cohort, such as 12q14.1 loci, which harbor CDK4. The association between CDK4 gain and innate resistance to anti–PD-1 therapy was validated in 85 patients with melanoma (P < 0.05). RNA-Seq analysis of CDK4-normal cell lines and CDK4-normal tumors showed altered transcriptional output in TNFα signaling via NF-κB, inflammatory response, and IFNγ response gene set. In addition, CDK4/6 inhibitor (palbociclib) treatment increased PD-L1 protein levels and enhanced efficacy (P < 0.05) in the C57BL/6-hPD-1 melanoma cell and the HIS PDX model. In summary, we discovered that genetic aberrations in the CDK4 pathway are associated with innate resistance to anti–PD-1 therapy in patients with advanced melanoma. Moreover, our study provides a strong rationale for combining CDK4/6 inhibitors with anti–PD-1 antibody for the treatment of advanced melanomas.

Usage metrics

    Clinical Cancer Research



    Ref. manager